April 22 (Bloomberg) — Novartis AG Chief Executive Officer Joe Jimenez talks about the agreement to buy GlaxoSmithKline Plc’s cancer-drug business for as much as $16 billion, forming a consumer-health venture with Glaxo and selling its animal-health operation to Eli Lilly & Co. for $5.4 billion.
He speaks from Basel, Switzerland, with Mark Barton and Anna Edwards on Bloomberg Television’s “Countdown.” (Source: Bloomberg)
Novartis AG agreed to buy GlaxoSmithKline Plc’s cancer drugs for as much as $16 billion while selling most of the company’s vaccines division to Glaxo for $7.1 billion and its animal-health unit to Eli Lilly & Co. for $5.4 billion.
April 22nd, 2014 at 6:40 am
From Bloomberg, Apr 22, 2014, 5:12:29 AM
He speaks from Basel, Switzerland, with Mark Barton and Anna Edwards on Bloomberg Television’s “Countdown.” (Source: Bloomberg)
Novartis AG agreed to buy GlaxoSmithKline Plc’s cancer drugs for as much as $16 billion while selling most of the company’s vaccines division to Glaxo for $7.1 billion and its animal-health unit to Eli Lilly & Co. for $5.4 billion.
To read the entire article, go to http://bloom.bg/1jtEv18
Sent from the Bloomberg iPad application. Download the free application at http://itunes.apple.com/us/app/bloomberg-for-ipad/id364304764?mt=8